In its Friday approval letter, the FDA didn’t explain the restrictions although they reflect skepticism about ...

The U.S. Food and Drug Administration on Friday approved Novavax's COVID-19 vaccine, but placed additional conditions on ...

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

FDA Commissioner Marty Makary said his agency plans to release a new framework for vaccine approvals in “coming days.” ...

Adults over the age of 60 are recommended not to get the chikungunya vaccine to prevent the mosquito-borne illness due to two ...

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.

The vaccine will only be available to those at high risk from Covid—excluding those who may need it to protect a relative or ...

Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

US regulators grant full approval to Novavax shot but sharply limit eligibility. New studies on heart risks required, raising ...

Novavax (NVAX) stock in focus as the U.S. FDA approves its COVID-19 vaccine Nuvaxovid for high-risk groups in the U.S. Read ...

The head of the Food and Drug Administration said the agency will soon unveil a new framework detailing what companies must do to seek approval of vaccines, a move that comes as the Trump ...